Results 241 to 249 of about 4,877,471 (249)

Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients. [PDF]

Antioxidants (Basel)
Mangione R, Giallongo C, Duminuco A, La Spina E, Longhitano L, Giallongo S, Tibullo D, Lazzarino G, Saab MW, Sbriglione A, Palumbo GA, Graziani A, Alanazi AM, Di Pietro V, Tavazzi B, Amorini AM, Lazzarino G.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Data‐driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis

European Journal of Haematology, 2021
Hydroxyurea (HU) treatment of patients with essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) (MPNs) normalizes elevated blood cell counts within weeks in the large majority of patients.
M. J. Dam, R. Pedersen, T. Knudsen, Morten Andersen, V. Skov, L. Kjaer, H. Hasselbalch, J. Ottesen   +7 more
semanticscholar   +1 more source

Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan

European Journal of Haematology, 2019
Prefibrotic/early primary myelofibrosis (pre‐PMF) and essential thrombocythemia (ET) exhibited different features of bone marrow; however, this is not always easy to judge objectively, making pathologists’ distinction often suboptimal.
Y. Edahiro, Marito Araki, Tadaaki Inano, Masafumi Ito, S. Morishita, K. Misawa, Y. Fukuda, M. Imai, A. Ohsaka, N. Komatsu   +9 more
semanticscholar   +1 more source

Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature

Clinical and Experimental Medicine (Testo stampato), 2020
G. Coltro, F. Mannelli, F. Vergoni, R. Santi, D. Massi, L. Siliani, A. Marzullo, S. Bonifacio, E. Pelo, Annalisa Pacilli, C. Paoli, A. Franci, L. Calabresi, A. Bosi, A. Vannucchi, P. Guglielmelli   +15 more
semanticscholar   +1 more source

A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.

Blood reviews, 2020
Benjamin Garmezy, J. Schaefer, Jessica Mercer, M. Talpaz   +3 more
semanticscholar   +1 more source

Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis.

Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis, 2022
M. Lucijanić, I. Krečak, E. Sorić, A. Sabljić, D. Galušić, H. Holik, V. Periša, M. Morić Perić, I. Zekanović, R. Kušec   +9 more
semanticscholar   +1 more source

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.

Journal of Clinical Oncology, 2018
A. Tefferi, P. Guglielmelli, T. Lasho, N. Gangat, R. Ketterling, A. Pardanani, A. Vannucchi   +6 more
semanticscholar   +1 more source

Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis

Annals of Hematology, 2019
P. Strati, M. Abdelrahim, U. Selamet, Valda D. Page, S. Pierce, S. Verstovsek, Ala Abudayyeh   +6 more
semanticscholar   +1 more source